NEW YORK (GenomeWeb News) — Upstream Biosciences has hired Genpathway to use its chromatin immunoprecipitation assays in its cancer biomarker-validation studies, Upstream Bio said today.

 

Genpathway will use its assays to “help elucidate critical parameters involving specific gene transcription factors and pathways” and provide “critical information for the next phase of Upstream's program to validate its first two cancer biomarkers and drug response assay,” according to Upstream.